SCHEMBL3147488

SCHEMBL3147488

COC(=O)C1CCCc2occc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.52
POLB P06746 3/20 0.52
GAA P10253 1/20 0.52
KDM4E B2RXH2 3/20 0.50
TSHR P16473 2/20 0.50
ALOX12 P18054 1/20 0.50
MAPT P10636 4/20 0.37
PKM P14618 1/20 0.37
HTR2C P28335 2/20 0.36
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
THRB P10828 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PRKDC P78527 1/20 0.32
IDH1 O75874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2049307 0.92 HSD17B10 (0.62) HSD17B10POLBGAAKDM4ETSHR
SCHEMBL3135266 0.78 HSD17B10 (0.35) HSD17B10POLBGAAKDM4ETSHR
SCHEMBL6198308 0.77 HSD17B10 (0.58) HSD17B10POLBGAAKDM4ETSHR
SCHEMBL3143570 0.77 HSD17B10 (0.34) HSD17B10POLBGAAKDM4EMAPT
SCHEMBL28738866 0.75 HSD17B10 (0.67) HSD17B10POLBGAAKDM4ETSHR
SCHEMBL3139450 0.74 KMT2A (0.43) HSD17B10KDM4ETSHRMAPTHTR2C
SCHEMBL2166539 0.74 NPC1 (0.44) HSD17B10KDM4ETSHRMAPTALDH1A1
SCHEMBL15475264 0.72 THRB (0.38) HSD17B10GAAKDM4ETSHRMAPT
SCHEMBL4873180 0.71 ALDH1A1 (0.42) HSD17B10POLBGAAKDM4EMAPT
SCHEMBL4875547 0.70 SMN1; SMN2 (0.43) HSD17B10KDM4ETSHRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 HSD17B10 2282/4885POLB 128/4885GAA 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.